A Phase 1 interventional study of ET-01 in Transfusion Dependent Beta-Thalassaemia, sponsored by EdiGene (GuangZhou) Inc.. Terminated at 4 sites in China. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by EdiGene (GuangZhou) Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.
Among the 44 studies in beta-Thalassemia with a site in China, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 1, and was the 16th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18–65
Bioray Laboratories · Sites in China
Ages 3–35
Guangzhou Women and Children's Medical Center · Sites in China
Ages 7–10
Children's Hospital of Fudan University · Sites in China
Ages 3–17
Kanglin Biotechnology (Hangzhou) Co., Ltd. · Sites in China
Ages 3–35
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1 · Phase 4 4
First in 2012; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 10 across the 34 interventional studies, 96 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 44 have an industry lead sponsor. The 10 most frequent:
EdiGene (GuangZhou) Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
EdiGene (GuangZhou) Inc. has 1 study filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
4 of the studies in beta-Thalassemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479616Children's Hospital of Fudan UniversityA Long-term Follow-up Study in Participants Who Received CS-101 | 2026-12 |
| NCT06308159Lantu BiopharmaAn Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia | 2027-08-01 |
| NCT05860595Institute of Hematology & Blood Diseases Hospital, ChinaEvaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. | 2027-08-20 |
| NCT06280378Kanglin Biotechnology (Hangzhou) Co., Ltd.β-Thalassemia Treatment With KL003 Cell Injection | 2027-11-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in beta-Thalassemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, open label, multi-center, single-dose phase 1 study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using ET-01.
Key Inclusion Criteria:
Other protocol defined inclusion criteria may apply.
Key Exclusion Criteria:
Other protocol defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ET-01
Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
Frequency and severity of collected AEs & SAEs
Time frame: Within 24 months after ET-01 infusion
All-cause mortality
Time frame: From signing of informed consent up to 24 months post-ET-01 infusion
Incidence of transplant-related mortality
Time frame: From baseline (pre-transfusion) up to 12 months post-ET-01 infusion
Total lymphocyte count
Time frame: Within 24 months after ET-01 infusion
Proportion of subjects with abnormal proliferation of blood cells
Time frame: Within 24 months after ET-01 infusion
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in Jan 2024, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ET-01
EdiGene (GuangZhou) Inc.